Cost-effectiveness analysis of basal/bolus therapy in type-1 diabetes using insulin detemir plus insulin aspart or human soluble insulin-based basal/bolus regimens in Germany

被引：0

作者：

Valentine, WJ

Wittrup-Jensen, KU

Palmer, AJ

Roze, S

机构：

[1] CORE Ctr Outcomes Res, Basel, Switzerland

[2] Novo Nordisk Pharma, Mainz, Germany

来源：

VALUE IN HEALTH | 2005年 / 8卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)67640-1

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A160 / A161

页数：2

共 50 条

[1] Comparison of the cost-effectiveness for basal-bolus therapy of type-1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens in the Netherlands
Valentine, WJ
Wittrup-Jensen, K
Palmer, AJ
Roze, S
[J]. VALUE IN HEALTH, 2005, 8 (03) : 255 - 255
[2] A comparison of the cost-effectiveness for basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Schmidt, I
Wittrup-Jensen, KW
[J]. DIABETES, 2004, 53 : A288 - A288
[3] A comparison of the cost-effectiveness of basal-bolus therapy of Type 1 diabetes using insulin detemir plus insulin aspart versus human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
[J]. DIABETOLOGIA, 2004, 47 : A344 - A344
[4] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
[J]. DIABETOLOGIA, 2005, 48 : A334 - A334
[5] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
[J]. DIABETES, 2005, 54 : A609 - A609
[6] Cost-effectiveness analyses of basal-bolus therapy of type-1 diabetes using insulin detemir plus human soluble insulin versus neutral protamine hagedorm plus human soluble insulin regimens in Germany
Valentine, WJ
Palmer, AJ
Wittrup-Jensen, KU
Roze, S
[J]. VALUE IN HEALTH, 2005, 8 (06) : A163 - A163
[7] Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes
Raslová, K
Bogoev, M
Raz, I
Leth, G
Gall, MA
Hancu, N
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) : 193 - 201
[8] Insulin detemir plus insulin aspart in a basal/bolus regiment delay the onset of diabetes related complications compared to a human basal/bolus regiment: A modeling study
Valentine, William J.
Lammert, Morten
Ray, Joshua A.
Roze, Stephane
Foos, Volker
Lurati, Francesco
Palmer, Andrew J.
[J]. DIABETES, 2006, 55 : A559 - A559
[9] COST-EFFECTIVENESS OF SWITCHING TO INSULIN ASPART FROM HUMAN SOLUBLE INSULIN IN CHINESE PATIENTS WITH TYPE-2 DIABETES ON A BASAL-BOLUS REGIMEN
Ji, Q. H.
Ye, Q.
Zhang, Y. Z.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A164 - A165
[10] Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes
Hermansen, K
Fontaine, P
Kukolja, KK
Peterkova, V
Leth, G
Gall, MA
[J]. DIABETOLOGIA, 2004, 47 (04) : 622 - 629

← 1 2 3 4 5 →